New Funds will Support Expanded Commercialization of the Revolutionary Accuri C6 Flow Cytometer® System

Funds to accelerate launch of diagnostic products to enable Biomarker-Guided Medicine

Raises $15M to Close Second Tranche of $25M Financing

WATERTOWN, Mass., Aug 06, 2008 (BUSINESS WIRE) -- Tetraphase Pharmaceuticals Inc. announced today that it has closed the second tranche of its $25 million Series A financing to support the advancement of several novel and potent antibiotic drug candidates. This second tranche of $15 million was funded by existing investors - Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

Affinnova Announces First Half 2008 Results

Waltham, MA – August 11, 2008 – Affinnova, Inc., the global leader in optimization technology for innovation and marketing, today announced growth results for the first half ended June 30, 2008.

First Half Highlights

Affinnova grew sales for the first half ended June 30, 2008 by 63% compared to the first half of 2007, an increase of 25% compared to the second half of 2007.

Leader in single molecule detection will utilize funds to advance SiMoA™ technology

BOSTON - (Business Wire) Novomer Inc., a materials company pioneering a family of high-performance, biodegradable plastics, polymers and other chemicals from renewable substances, today announced that it has been honored by AlwaysOn as one of the GoingGreen Top 100 Winners. Novomer was selected by the AlwaysOn editorial team and other industry experts spanning the globe, based on a set of five criteria: innovation, market potential, commercialization, stakeholder value and media buzz.

SCH900105 (AV-299) Marks First of Several Monoclonal Antibodies from AVEO’s Discovery Platform; Trial Triggers Milestone Under Agreement with Schering Plough

Results Presented at the North American Menopause Society’s 2008 Annual Meeting

Leader in single molecule protein detection will utilize funds to develop single molecule arrays for the detection of low abundance cancer proteins

Lexington, MA (October 6, 2008) – Concert Pharmaceuticals, Inc. today announced that Steven B. Bernitz has joined the company as its Senior Vice President and Chief Business Officer. In this role, he will be a member of Concert’s executive management team, designing and implementing strategic planning initiatives and having overall responsibility for Concert’s business development activities. Mr. Bernitz replaces Jeffrey Williams who now serves as a consultant to the company.